FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 343:510-511 August 17, 2000 Number 7 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Bodenheimer, T. PubMed Citation

To the Editor: Although Dr. Bodenheimer (May 18 issue)¹ makes a number of cogent observations about the sponsorship of clinical research by the pharmaceutical industry, his report lacks balance. As an employee of a contract-research organization (CRO), I have a different viewpoint.

Without providing supporting data, Dr. Bodenheimer concludes that drug trials conducted by CROs and other commercial entities are "heavily tipped toward industry interests" and that these organizations "will fail if they offend their funding sources." In fact, CROs have no vested or commercial interests in study outcomes. Such companies do not manufacture or sell pharmaceuticals, and the positive . . . [Full Text of this Article]

References

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2008 Massachusetts Medical Society. All rights reserved.